New depression pill shows promise for those failed by standard meds
NCT ID NCT06340958
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This study tested an experimental drug called CLE-100 (oral esketamine) in 99 adults with major depression who did not get enough relief from at least two standard antidepressants. Participants took CLE-100 or a placebo alongside their current antidepressant for several weeks. The goal was to see if adding CLE-100 could safely improve depression symptoms better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site 101
Toms River, New Jersey, 08755, United States
-
Clinical Site 102
Hollywood, Florida, 33024, United States
-
Clinical Site 103
Beachwood, Ohio, 44236, United States
-
Clinical Site 105
Lauderhill, Florida, 33319, United States
-
Clinical Site 107
Austin, Texas, 78737, United States
-
Clinical Site 108
Gaithersburg, Maryland, 20877, United States
-
Clinical Site 114
Savannah, Georgia, 31405, United States
-
Clinical Site 115
Bellevue, Washington, 98007, United States
-
Clinical Site 116
Flowood, Mississippi, 39232, United States
-
Clinical Site 117
Murray, Utah, 84107, United States
-
Clinical Site 118
Atlanta, Georgia, 30030, United States
-
Clinical Site 119
North Canton, Ohio, 44720, United States
-
Clinical Site 120
Elgin, Illinois, 60123, United States
-
Clinical Site 126
O'Fallon, Missouri, 63368, United States
-
Clinical Site 127
Chicago, Illinois, 60640, United States
-
Clinical Site 130
Upland, California, 91786, United States
-
Clinical Site 131
Lafayette, California, 94549, United States
-
Clinical Site 132
Pensacola, Florida, 32502, United States
-
Clinical Site 135
Oklahoma City, Oklahoma, 73112, United States
-
Clinical Site 137
Plano, Texas, 75093, United States
-
Clinical Site 138
Marietta, Georgia, 30060, United States
-
Clinical Site 139
La Jolla, California, 92037, United States
-
Clinical Site 140
Miami Springs, Florida, 33166, United States
Conditions
Explore the condition pages connected to this study.